Cell models with inducible oncogenic translocations allow to evaluate the potential of drugs to favor secondary translocations

Cancer Commun (Lond). 2023 Jan;43(1):154-158. doi: 10.1002/cac2.12370. Epub 2022 Oct 17.

Anna Shmakova^{1

2

3}, Nikolai Lomov^{1

4}, Vladimir Viushkov⁴, Tatyana Tsfasman¹, Yana Kozhevnikova^{1

5}, Darina Sokolova^{6

7

8}, Vadim Pokrovsky^{6

7

8}, Marina Syrkina⁴, Diego Germini¹, Mikhail Rubtsov^{4

9}, Yegor Vassetzky^{1

2}

¹ UMR9018, Université Paris-Saclay, Centre national de la recherche scientifique, Gustave Roussy, Villejuif, 94805, France.
² Koltzov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, 119334, Russia.
³ Institute of Experimental Cardiology, National Medical Research Centre of Cardiology, Moscow, 121552, Russia.
⁴ Department of Molecular Biology, Faculty of Biology, Lomonosov Moscow State University, Leninskie Gory, Moscow, 119991, Russia.
⁵ Faculty of Medicine, Lomonosov Moscow State University, Moscow, 119991, Russia.
⁶ Laboratory of Combined Treatment, Blokhin Cancer Research Center, Moscow, 115478, Russia.
⁷ Department of Biochemistry, Peoples' Friendship University of Russia, Moscow, 117198, Russia.
⁸ Center of Genetics and Life Sciences, Sirius University of Science and Technology, Federal Territory Sirius, Sochi, 354340, Russia.
⁹ Department of Biochemistry, Center for Industrial Technologies and Entrepreneurship, Sechenov First Moscow State Medical University, Moscow, 119991, Russia.

No abstract available

Publication types